Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients

A randomized double-blind placebo-controlled trial

Suleyman Turk, Aysegul Baki, Yalcin Solak, Mehmet Kayrak, Huseyin Atalay, Abduzhappar Gaipov, Alpay Aribas, Hakan Akilli, Zeynep Biyik, Nilsel Okudan, Hakki Gokbel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.

Original languageEnglish (US)
Pages (from-to)374-381
Number of pages8
JournalHemodialysis International
Volume17
Issue number3
DOIs
StatePublished - Jul 1 2013

Fingerprint

coenzyme Q10
Renal Dialysis
Placebos
Heart Ventricles
Maintenance
Doppler Echocardiography

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients : A randomized double-blind placebo-controlled trial. / Turk, Suleyman; Baki, Aysegul; Solak, Yalcin; Kayrak, Mehmet; Atalay, Huseyin; Gaipov, Abduzhappar; Aribas, Alpay; Akilli, Hakan; Biyik, Zeynep; Okudan, Nilsel; Gokbel, Hakki.

In: Hemodialysis International, Vol. 17, No. 3, 01.07.2013, p. 374-381.

Research output: Contribution to journalArticle

Turk, S, Baki, A, Solak, Y, Kayrak, M, Atalay, H, Gaipov, A, Aribas, A, Akilli, H, Biyik, Z, Okudan, N & Gokbel, H 2013, 'Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: A randomized double-blind placebo-controlled trial', Hemodialysis International, vol. 17, no. 3, pp. 374-381. https://doi.org/10.1111/hdi.12022
Turk, Suleyman ; Baki, Aysegul ; Solak, Yalcin ; Kayrak, Mehmet ; Atalay, Huseyin ; Gaipov, Abduzhappar ; Aribas, Alpay ; Akilli, Hakan ; Biyik, Zeynep ; Okudan, Nilsel ; Gokbel, Hakki. / Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients : A randomized double-blind placebo-controlled trial. In: Hemodialysis International. 2013 ; Vol. 17, No. 3. pp. 374-381.
@article{d9bd273582a041e6bf737c3df6c8aa68,
title = "Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: A randomized double-blind placebo-controlled trial",
abstract = "Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.",
author = "Suleyman Turk and Aysegul Baki and Yalcin Solak and Mehmet Kayrak and Huseyin Atalay and Abduzhappar Gaipov and Alpay Aribas and Hakan Akilli and Zeynep Biyik and Nilsel Okudan and Hakki Gokbel",
year = "2013",
month = "7",
day = "1",
doi = "10.1111/hdi.12022",
language = "English (US)",
volume = "17",
pages = "374--381",
journal = "Hemodialysis International",
issn = "1492-7535",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients

T2 - A randomized double-blind placebo-controlled trial

AU - Turk, Suleyman

AU - Baki, Aysegul

AU - Solak, Yalcin

AU - Kayrak, Mehmet

AU - Atalay, Huseyin

AU - Gaipov, Abduzhappar

AU - Aribas, Alpay

AU - Akilli, Hakan

AU - Biyik, Zeynep

AU - Okudan, Nilsel

AU - Gokbel, Hakki

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.

AB - Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.

UR - http://www.scopus.com/inward/record.url?scp=84879600702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879600702&partnerID=8YFLogxK

U2 - 10.1111/hdi.12022

DO - 10.1111/hdi.12022

M3 - Article

VL - 17

SP - 374

EP - 381

JO - Hemodialysis International

JF - Hemodialysis International

SN - 1492-7535

IS - 3

ER -